![]() |
![]() |
![]() |
![]() |
![]() |
Why people rush for iodine tablets over nuclear, cancer risk Paris, March 8 (AFP) Mar 08, 2022 European countries have seen stocks of iodine fly off the shelves due to fears it may be needed to counter the risks of thyroid cancer if Russia's invasion of Ukraine causes a nuclear incident. France said it would send 2.5 million doses of the chemical compound to Ukraine after Russian forces there seized the defunct Chernobyl nuclear site and damaged Zaporizhzhia, Europe's largest atomic plant. Here are some facts about iodine.
- Can iodine help in a nuclear accident? -
Tablets of stable, non-radioactive iodine help prevent radioactive iodine concentrating in the thyroid gland. Saturated like a sponge with stable iodine, the gland can no longer capture the radioactive element, which is then flushed out of the body naturally though the urine. - Does iodine work in all circumstances? -
The French Nuclear Safety Authority (ASN) told AFP that iodine only protects the thyroid and the most important thing to do in a nuclear incident is to take shelter in a hard building. The tablets must be taken at precise times -- ideally, one hour before exposure to radiation and, at the latest, in the 6 to 12 hours following exposure. They are recommended in particular for pregnant women, babies, children and young people. "There is no point in taking iodine tablets as a prophylactic," the ASN warned. "It's pointless and it can cause undesirable effects or allergies." Taking too much iodine can cause the thyroid to malfunction and damage the heart and kidneys. Last week Croatian doctors warned of the dangers of taking iodine without proper precautions. Belgians have also been warned of the risks but have nonetheless reportedly rushed to buy the pills.
In France, for example, there have been five iodine distribution campaigns since 1997, in reaction to accidental radioactive leaks from nuclear sites. ito-ic/fmp/abl/oaa/gil/rlp
|
|
All rights reserved. Copyright Agence France-Presse. Sections of the information displayed on this page (dispatches, photographs, logos) are protected by intellectual property rights owned by Agence France-Presse. As a consequence, you may not copy, reproduce, modify, transmit, publish, display or in any way commercially exploit any of the content of this section without the prior written consent of Agence France-Presse.
|